Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, granted equity awards on August 31, 2015, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to nine individuals hired by Sarepta in August 2015. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 88,000 shares of Sarepta’s common stock. The options have an exercise price of $35.70 per share, which is equal to the closing price of Sarepta’s common stock on August 31, 2015. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates. (Original Source)
Shares of Sarepta Therapeutics closed today at $35.70, down $0.99 or 2.70%. SRPT has a 1-year high of $37.39 and a 1-year low of $11.33. The stock’s 50-day moving average is $33.43 and its 200-day moving average is $22.63.
On the ratings front, Sarepta Therapeutics has been the subject of a number of recent research reports. In a report issued on August 26, RBC analyst Simos Simeonidis upgraded SRPT to Buy, with a price target of $62, which implies an upside of 73.7% from current levels. Separately, on the same day, Roth Capital’s Debjit Chattopadhyay maintained a Buy rating on the stock and has a price target of $50.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Simos Simeonidis and Debjit Chattopadhyay have a total average return of -17.6% and 24.9% respectively. Simeonidis has a success rate of 25.7% and is ranked #3681 out of 3743 analysts, while Chattopadhyay has a success rate of 57.6% and is ranked #25.
Overall, 4 research analysts have assigned a Hold rating and 7 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $35.00 which is -2.0% under where the stock opened today.
Sarepta Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.